Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SAR444245 combinations in lung cancer or pleural mesothelioma
2020-005331-78Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegenzileukin in bronchial carcinoma and pleural mesothelioma, sponsored by Sanofi. Primary endpoint: Objective response rate. Started Jun 2021; status: completed.
02
Drugs
pegenzileukin
03
Conditions
bronchial carcinomapleural mesothelioma
Beyond the preview
Go deeper on 2020-005331-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005331-78.